Uveitis Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Uveitis Treatment Market by Drug Class (Corticosteroids, Immunosuppressant, Monoclonal antibodies, Antibiotics, Antivirals, Antifungal, Analgesics) and Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Panuveitis) Cause (Infectious Uveitis, Non-Infectious Uveitis), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Others)- Geography 

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Uveitis Treatment Market size was valued at 581 million in 2021 and is expected to reach 857 million by 2028, at a CAGR of 5.7% during the forecast period 2022 to 2028. Market players are developing novel molecules that can treat uveitis conditions in order to enhance their sales revenue. Companies are focusing on the development of the various drugs in the treatment of the uveitis. For instance, Aurinia Pharmaceuticals Inc. developing Luvenia, a calcineurin inhibitor for the treatment of noninfectious uveitis. Recently it has completed its phase-II clinical trials. Similarly, other pipeline drugs such as EMEA, DE-109, Gevokizumab, Peptide B27PD are being developed by different companies. Considering the aforementioned factors global uveitis treatment market is expected to grow at the significant rate during the forecast period. Uveitis is the term that describes a group of inflammatory diseases that affect the eye and produces swelling. Uveitis can reduce sight and may cause vision loss. Causes of uveitis include infections such as brucellosis, leptospirosis, syphilis, tuberculosis, autoimmune diseases such as sarcoidosis, Crohn’s disease, multiple sclerosis, arthritis, ankylosing spondylitis, and psoriatic arthritis. In addition, uveitis is also caused by drugs such as rifabutin and moxifloxacin. Uveitis affects uvea, lens, retina, optic nerve, and vitreous. Uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis and pan-uveitis based on part of inflammation.

Uveitis Treatment Market

MARKET SUMMARY
-
5.7%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 5.7%
  • Largest Market– Europe
  • Fastest Growing Market– North-America

Uveitis Treatment Market

  • The global uveitis treatment market report gives comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The report on global market gives historical, current, and future market sizes (US$ Mn) on the basis of drug class, disease type, by cause, distribution channel and region.
Key Players
  • AbbVie Inc.,
  • Eyegate Pharmaceuticals Inc.,
  • Valeant Pharmaceuticals (Bausch + Lomb),
  • Novartis AG,
  • Alimera Sciences Inc.
  • Santen Pharmaceutical Co. Ltd.
Uveitis Treatment Market

DRIVERS AND RESTRAINTS

The main driver for the growth of uveitis market is the rise in prevalence and complications related to uveitis. In addition, increase in prevalence rates, market players betting heavily on research and development to develop new drugs, an introduction of biologics into the market, fast approval of the drugs are fueling the market growth of uveitis treatment market. According to the Ocular Immunology and Uveitis Foundation, worldwide 2,359,242 people are estimated to have the disorder. Even there are significant advances in research and therapeutics, a prevalence of blindness secondary to uveitis has not been reduced in the past thirty years. However, few factors are restraining the growth of the market such as side effects of the drugs, eye irritation and lack of awareness about eye disorders in undeveloped regions, lack of sufficient healthcare infrastructure is hindering the uveitis treatment system market.


North-America Got Significant Share

Uveitis Treatment Market

Geographically global uveitis treatment market segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is leading in uveitis treatment market due to various factors such as early approval of drugs compared to other regions, increased R&D investments by market players, and high prevalence of the uveitis is contributing growth of the market. In Europe region due to increased prevalence of diseases such as HIV, multiple sclerosis that are underlying causes of uveitis conditions. Japan, China, and India are expected to play important role in the revenue growth of the Asia-Pacific uveitis treatment market. China and India market growth is due to rapidly developing healthcare infrastructure, increased research and development expenditure and growing awareness about the eye-related diseases. However, manufacturing of eye preparations required aseptic conditions and the manufacturing plant should be GMP certified. Hence the cost related to these preparations is very high that has the direct implication on a cost of the drugs.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Developments

  • In June 2019, U.S. Food and Drug Administration approved AbbVie’s HUMIRA for the treatment of non-infectious intermediate, posterior and panuveitis

Key

Uveitis Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

1. Executive summary
2. Global Uveitis Treatment Market Introduction
2.1. Global Uveitis Treatment Market – Taxonomy
2.2. Global Uveitis Treatment Market –Definitions
2.2.1. Drug Class Type
2.2.2. Disease Type
2.2.3. Cause
2.2.4. Distribution Channel
3. Global Uveitis Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Uveitis Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Uveitis Treatment Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Uveitis Treatment Market – Product Innovations
4. Global Uveitis Treatment Market Analysis, 2017 – 2021and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. Global Uveitis Treatment Market, By Drug Class, 2017 – 2021and Forecast, 2017 – 2023
5.1. Corticosteroids
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3. Market Opportunity Analysis
5.2. Immunosuppressant
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.3. Market Opportunity Analysis
5.3. Monoclonal antibodies
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.3.3. Market Opportunity Analysis
5.4. Antibiotics
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.4.3. Market Opportunity Analysis
5.5. Antivirals
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.5.3. Market Opportunity Analysis
5.6. Antifungal
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.6.3. Market Opportunity Analysis
5.7. Analgesics
5.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.7.3. Market Opportunity Analysis
6. Global Uveitis Treatment Market Forecast, By Disease Type, 2017 – 2021and Forecast, 2017 – 2023
6.1. Anterior Uveitis
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Posterior Uveitis
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Intermediate Uveitis
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.3.3. Market Opportunity Analysis
6.4. Panuveitis
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.4.3. Market Opportunity Analysis
7. Global Uveitis Treatment Market Forecast, By Cause, 2017 – 2021and Forecast, 2017 – 2023
7.1. Infectious Uveitis
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Non-Infectious Uveitis
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
8. Global Uveitis Treatment Market Forecast, By Distribution Channel, 2017 – 2021and Forecast, 2017 – 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Others
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
9. Global Uveitis Treatment Market Forecast, By Region, 2017 – 2021and Forecast, 2017 – 2023
9.1. North America
9.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.5.3. Market Opportunity Analysis
9.6. Global Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class Type, By Disease Type, Cause,  Distribution Channel, and Region, 2022 – 2028
10. North America Uveitis Treatment Market Analysis, 2017 – 2021and Forecast, 2017 – 2023
10.1.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Corticosteroids
10.1.1.2. Immunosuppressant
10.1.1.3. Monoclonal antibodies
10.1.1.4. Antibiotics
10.1.1.5. Antivirals
10.1.1.6. Antifungal
10.1.1.7. Analgesics
10.1.2. Disease Type Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Anterior Uveitis
10.1.2.2. Posterior Uveitis
10.1.2.3. Intermediate Uveitis
10.1.2.4. Panuveitis
10.1.3. Cause Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Infectious Uveitis
10.1.3.2. Non Infectious Uveitis
10.1.4. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Hospital Pharmacies
10.1.4.2. Retail Pharmacies
10.1.4.3. Others
10.1.5. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.1.5.1. U.S.
10.1.5.2. Canada
10.1.6. North America Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2022 – 2028
10.1.7. North America Uveitis Treatment Market Dynamics – Trends
11. Europe Uveitis Treatment Market Analysis, 2017 – 2021and Forecast, 2017 – 2023
11.1.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Corticosteroids
11.1.1.2. Immunosuppressant
11.1.1.3. Monoclonal antibodies
11.1.1.4. Antibiotics
11.1.1.5. Antivirals
11.1.1.6. Antifungal
11.1.1.7. Analgesics
11.1.2. Disease Type Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Anterior Uveitis
11.1.2.2. Posterior Uveitis
11.1.2.3. Intermediate Uveitis
11.1.2.4. Panuveitis
11.1.3. Cause Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Infectious Uveitis
11.1.3.2. Non Infectious Uveitis
11.1.4. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.4.1. Hospital Pharmacies
11.1.4.2. Retail Pharmacies
11.1.4.3. Others
11.1.5. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.5.1. Germany
11.1.5.2. UK
11.1.5.3. France
11.1.5.4. Spain
11.1.5.5. Italy
11.1.5.6. Russia
11.1.5.7. Poland
11.1.5.8. Rest of Europe
11.1.6. Europe Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2022 – 2028
11.1.7. Europe Uveitis Treatment Market Dynamics – Trends
12. Asia-Pacific Uveitis Treatment Market Analysis, 2017 – 2021and Forecast, 2017 – 2023
12.1.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Corticosteroids
12.1.1.2. Immunosuppressant
12.1.1.3. Monoclonal antibodies
12.1.1.4. Antibiotics
12.1.1.5. Antivirals
12.1.1.6. Antifungal
12.1.1.7. Analgesics
12.1.2. Disease Type Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Anterior Uveitis
12.1.2.2. Posterior Uveitis
12.1.2.3. Intermediate Uveitis
12.1.2.4. Panuveitis
12.1.3. Cause Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Infectious Uveitis
12.1.3.2. Non Infectious Uveitis
12.1.4. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Hospital Pharmacies
12.1.4.2. Retail Pharmacies
12.1.4.3. Others
12.1.5. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.1.5.1. Japan
12.1.5.2. China
12.1.5.3. India
12.1.5.4. ASEAN
12.1.5.5. Australia & New Zealand
12.1.5.6. Rest of Asia-Pacific
12.1.6. Asia-Pacific Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2022 – 2028
12.1.7. Europe Uveitis Treatment Market Dynamics – Trends
13. Latin America Uveitis Treatment Market Analysis, 2017 – 2021and Forecast, 2017 – 2023
13.1.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Corticosteroids
13.1.1.2. Immunosuppressant
13.1.1.3. Monoclonal antibodies
13.1.1.4. Antibiotics
13.1.1.5. Antivirals
13.1.1.6. Antifungal
13.1.1.7. Analgesics
13.1.2. Disease Type Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Anterior Uveitis
13.1.2.2. Posterior Uveitis
13.1.2.3. Intermediate Uveitis
13.1.2.4. Panuveitis
13.1.3. Cause Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Infectious Uveitis
13.1.3.2. Non Infectious Uveitis
13.1.4. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.4.1. Hospital Pharmacies
13.1.4.2. Retail Pharmacies
13.1.4.3. Others
13.1.5. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.5.1. Brazil
13.1.5.2. Mexico
13.1.5.3. Argentina
13.1.5.4. Venezuela
13.1.5.5. Rest of Latin America
13.1.6. Latin America Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2022 – 2028
13.1.7. Latin America Uveitis Treatment Market Dynamics – Trends
14. Middle East and Africa Uveitis Treatment Market Analysis, 2017 – 2021and Forecast, 2017 – 2023
14.1.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1.1. Corticosteroids
14.1.1.2. Immunosuppressant
14.1.1.3. Monoclonal antibodies
14.1.1.4. Antibiotics
14.1.1.5. Antivirals
14.1.1.6. Antifungal
14.1.1.7. Analgesics
14.1.2. Disease Type Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.2.1. Anterior Uveitis
14.1.2.2. Posterior Uveitis
14.1.2.3. Intermediate Uveitis
14.1.2.4. Panuveitis
14.1.3. Cause Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.3.1. Infectious Uveitis
14.1.3.2. Non Infectious Uveitis
14.1.4. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.4.1. Hospital Pharmacies
14.1.4.2. Retail Pharmacies
14.1.4.3. Others
14.1.5. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.5.1. Gulf Cooperation Council (GCC) Countries
14.1.5.2. Israel
14.1.5.3. South Africa
14.1.5.4. Rest of MEA
14.1.6. MEA Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2022 – 2028
14.1.7. MEA Uveitis Treatment Market Dynamics – Trends
15. Competition Landscape 
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. AbbVie Inc. (U.S.)
15.2.2. Eyegate Pharmaceuticals Inc. (U.S.)
15.2.3. Valeant Pharmaceuticals (Bausch + Lomb) (Canada)
15.2.4. Novartis AG (Switzerland)
15.2.5. Alimera Sciences Inc. (U.S.)
15.2.6. Santen Pharmaceutical Co. Ltd (Japan)
16. Research Methodology
17. Key Assumptions and Acronyms

Report

Company Profile

  • AbbVie Inc. (U.S.)
  • Eyegate Pharmaceuticals Inc. (U.S.)
  • Valeant Pharmaceuticals (Bausch + Lomb) (Canada)
  • Novartis AG (Switzerland)
  • Alimera Sciences Inc. (U.S.)
  • Santen Pharmaceutical Co. Ltd (Japan)

Description

Uveitis Treatment Market size was valued at 581 million in 2021 and is expected to reach 857 million by 2028, at a CAGR of 5.7% during the forecast period 2022 to 2028. Market players are developing novel molecules that can treat uveitis conditions in order to enhance their sales revenue. Companies are focusing on the development of the various drugs in the treatment of the uveitis. For instance, Aurinia Pharmaceuticals Inc. developing Luvenia, a calcineurin inhibitor for the treatment of noninfectious uveitis. Recently it has completed its phase-II clinical trials. Similarly, other pipeline drugs such as EMEA, DE-109, Gevokizumab, Peptide B27PD are being developed by different companies. Considering the aforementioned factors global uveitis treatment market is expected to grow at the significant rate during the forecast period. Uveitis is the term that describes a group of inflammatory diseases that affect the eye and produces swelling. Uveitis can reduce sight and may cause vision loss. Causes of uveitis include infections such as brucellosis, leptospirosis, syphilis, tuberculosis, autoimmune diseases such as sarcoidosis, Crohn’s disease, multiple sclerosis, arthritis, ankylosing spondylitis, and psoriatic arthritis. In addition, uveitis is also caused by drugs such as rifabutin and moxifloxacin. Uveitis affects uvea, lens, retina, optic nerve, and vitreous. Uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis and pan-uveitis based on part of inflammation.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX